Table 1.

Mean number and proportion of severe cases averted due to distribution of oral antivirals at 10% and 90% vaccination coverage

Country	Testing rate (tests/100,000 people/day)	Re	10% vaccination coverage		90% vaccination coverage
			No. of severe cases averted	Proportion of severe cases averted	No. of severe cases averted	Proportion of severe cases averted
Zambia	10	0.9	29	2.7	3	1.1
		1.2	16	0.3	20	1.1
		1.5	0	0.0	0	0.0
		2.0	22	0.2	32	0.7
	100	0.9	147	16.9	48	20.1
		1.2	170	3.3	72	4.4
		1.5	172	1.9	131	3.7
		2.0	0	0.0	0	0.0
	500	0.9	242	35.0	102	45.6
		1.2	1053	26.5	441	38.0
		1.5	780	9.0	527	16.4
		2.0	824	7.2	433	8.8
Brazil	10	0.9	0	0.0	10	2.8
		1.2	0	0.0	59	3.2
		1.5	0	0.0	13	0.2
		2.0	61	0.2	0	0.0
	100	0.9	303	23.7	133	54.6
		1.2	623	6.4	195	13.6
		1.5	245	1.2	196	3.7
		2.0	305	1.2	24	0.2
	500	0.9	511	47.4	134	55.3
		1.2	2739	43.1	545	55.4
		1.5	2005	10.7	1404	35.7
		2.0	1553	6.1	872	9.4
Georgia	10	0.9	0	0.0	0	0.0
		1.2	282	2.1	0	0.0
		1.5	163	0.4	80	1.2
		2.0	34	0.1	148	0.9
	100	0.9	635	49.9	170	65.3
		1.2	1459	13.4	336	29.6
		1.5	929	2.6	483	8.7
		2.0	415	0.8	284	1.7
	500	0.9	792	63.4	167	63.5
		1.2	4344	65.3	597	66.9
		1.5	7481	24.3	2270	66.1
		2.0	4435	8.4	2115	13.6
Netherlands	10	0.9	298	14.4	0	0.0
		1.2	243	1.8	0	0.0
		1.5	183	0.5	133	2.0
		2.0	0	0.0	22	0.1
	100	0.9	598	48.2	171	66.6
		1.2	2333	20.1	362	30.7
		1.5	953	2.7	419	7.5
		2.0	854	1.5	0	0.0
	500	0.9	811	63.1	185	67.0
		1.2	4857	68.5	604	67.3
		1.5	8947	28.0	2123	65.1
		2.0	3190	5.9	2960	18.1

No restrictions on access to symptomatic testing at clinics (i.e., all symptomatic individuals who sought testing at clinics would receive one if in stock) and high-risk household contacts of test-positive individuals are not tested. The average values tabulated are based on results from five independent simulations.